Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014, Article ID 671050, 8 pages
http://dx.doi.org/10.1155/2014/671050
Research Article

Genetic Diversity of MSP1 Block 2 of Plasmodium vivax Isolates from Manaus (Central Brazilian Amazon)

1Instituto Leonidas e Maria Deane, Fundação Oswaldo Cruz, Rua Teresina 476 Adrianópolis, 69057-070 Manaus, AM, Brazil
2Universidade Federal do Amazonas, Programa Multi-Institucional de Pós-Graduação em Biotecnologia (PPGBIOTEC) Avenida Rodrigo Otávio Jordão Ramos 3000, Coroado, Manaus, AM, Brazil
3Hospital Fundação de Medicina Tropical Dr. Heitor Vieira Dourado, Avenida Pedro Teixeira 25, Dom Pedro, 69.040-000 Manaus, AM, Brazil

Received 5 December 2013; Accepted 9 January 2014; Published 27 February 2014

Academic Editor: Wuelton Marcelo Monteiro

Copyright © 2014 Leidiane Amorim Soares et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The diversity of MSP1 in both Plasmodium falciparum and P. vivax is presumed be associated to parasite immune evasion. In this study, we assessed genetic diversity of the most variable domain of vaccine candidate N-terminal PvMSP1 (Block 2) in field isolates of Manaus. Forty-seven blood samples the polymorphism of PvMSP1 Block 2 generates four fragment sizes. In twenty-eight of them, sequencing indicated seven haplotypes of PvMSP1 Block 2 circulating among field isolates. Evidence of striking exchanges was observed with two stretches flanking the repeat region and two predicted recombination sites were described. Single nucleotide polymorphisms determined with concurrent infections per patient indicated that nonsynonymous substitutions occurred preferentially in the repeat-rich regions which also were predicted as B-cell epitopes. The comprehensive understanding of the genetic diversity of the promising Block 2 associated with clinical immunity and a reduced risk of infection by Plasmodium vivax would be important for the rationale of malaria vaccine designs.